Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Innovative Therapies for Oncogenic KRAS Mutations: Precision Strategies with PROTACs in Cancer Treatment.

Anti-cancer agents in medicinal chemistry - 1 Jan 2026

Halagali Praveen, Sharma Himanshu, Rathnanand Mahalaxmi, Tippavajhala Vamshi Krishna

Abstract excerpt

The KRAS (Kirsten rat sarcoma viral oncogene homolog) gene mutation is commonly found in colorectal, lung, and pancreatic carcinomas. Unfortunately, blocking KRAS straight away has proven to be challenging. PROTACs (Proteolysis Targeting Chimeras), a class of bifunctional molecules, are designed to break down proteins, offering a unique strategy to target KRAS and overcome the limitations of traditional...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to KRAS gene

Share to Mutation

Share to Neoplasms

Share to Proteolysis

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 40468924
DOI: 10.2174/0118715206377691250523095407

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Innovative Therapies for Oncogenic KRAS Mutations: Precision Strategies with PROTACs in Cancer Treatment.PMID 40468924Read ↗

Research progress of direct and indirect KRAS-targeting protein degraders in KRAS-mutant cancers.Semantic proximity Read ↗

Recent advances in targeted degradation in the RAS pathway.Semantic proximity Read ↗

Current Strategies and Future Dimensions in the Development of KRAS Inhibitors for Targeted Anticancer Therapy.Semantic proximity Read ↗

Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers.Semantic proximity Read ↗

Targeting the Interplay of Proteins through PROTACs for the Management of Cancer and Associated DisordersSemantic proximity Read ↗

Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers.Semantic proximity Read ↗

A pan-KRAS degrader for the treatment of KRAS-mutant cancersSemantic proximity Read ↗

Strategies for Targeting KRAS: A Challenging Drug Target.Semantic proximity Read ↗

Discovery of highly potent and selective KRASG12C degraders by VHL-recruiting PROTACs for the treatment of tumors with KRASG12C-Mutation.Semantic proximity Read ↗

Small-molecule degraders for oncogenic KRASG12C and pan-KRAS mutations.Semantic proximity Read ↗

Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors.Semantic proximity Read ↗

Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.